Description  Claims  Cited references 

GB1238868A   [0009] 
US5973026A   [0009] 
JP2009096766A   [0009] 
WO2008055843A   [0009] 
CA2508094A   [0009] 
US5965615A   [0009] 
US2007191381A   [0009] 
EP2070529A1   [0009] 
WO2010149654A   [0009] 
US4481218A   [0010] 
US4451485A   [0010] 
EP2070529B   [0014] 
EP0845986B   [0014] 

Gamma-Butyrobetain, Crotonbetain und Carnitin im tierischen Stoffwechsel   [0007] 
Iber die Toxizitat des Carnitins und einiger verwandter Stoffe   [0007] 
Pharmacological actions of y-butyrobetaine   [0008] 
Isolation and probable functions of betaine esters in brain metabolism   [0008] 
A comparison of glycine, sarcosine, N,N-dimethylglycine, glycinebetaine and N-modified betaines as liposome cryoprotectants   [0009] 
Synthesis, Characterization, and Aqueous Solution Behavior of Electrolyte- and pH-Responsive Carboxybetaine-Containing Cyclocopolymers   [0009] 
Prelog V.   [0009] 
I. Mildronate: cardioprotective action through carnitine-lowering effect   [0011] 
Clinical Efficacy and Safety of Mildronate in Patients With Ischemic Heart Disease and Chronic Heart Failure   [0012] 
3-(2,2,2,-Trimethylhydrazinium)propionate (THP) - a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties   [0013] 
Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction   [0013] 
J. Cardiovasc. Pharmacol.   [0032]